COSM News & Events

Cosmos Health sees FY26 revenue surpassing $90M, one est. $87.3M

Cosmos Health announced guidance for the 2026-2029 period. "Momentum has carried into 2026 across all core segments, with the company expecting to surpass $90M in revenue in 2026, representing approximately 38% year-over-year growth, and continued strong growth anticipated through 2029. By 2029, Cosmos Health projects revenue of $200.6M, gross profit of $71.2M, net income of $31M, Adjusted EBITDA of $44.2M, and cash of $62.9M, with all convertible debt expected to be fully repaid and stockholders' equity projected to increase 402% to $92.3M. Management believes this financial trajectory could create a powerful compounding effect across the company's operations, balance sheet, and profitability profile - supporting its long-term vision of building a leading diversified healthcare platform through scalable, higher-margin growth." Revenue is projected to increase by 207% at a 32% CAGR, from $65.3M in 2025 to $200.6M in 2029, the company said.

Greg Siokas, CEO of Cosmos Health, stated: "Q1 2026 was a record Q1 for Cosmos Health, with revenue of $17.93 million, up 31% year-over-year and 34% on an adjusted basis, reflecting broad-based commercial momentum across every major division - record distribution volumes at CosmoFarm, continued global expansion of Sky Premium Life, and new contract manufacturing agreements at Cana Laboratories."

Cosmos Health announced that, through its wholly owned subsidiary Cana Laboratories, it is pursuing a strategic research and development financing program with the European Investment Bank, EIB, the financing arm of the European Union and one of the world's largest multilateral lenders. In connection with this initiative, Cana Laboratories has entered into an advisory agreement with the EIB to support the Company's progress under the EIB-backed financing program. The agreement represents an important milestone for the Company and reflects the alignment of its R&D initiatives with the EIB's evaluation criteria. Cosmos Health believes the process could support access to long-term institutional financing on attractive terms with limited dilution.